Colon Pharmaceutical announced that the application for a new drug of the company's holding subsidiary, Bodutrastuzumab, the core product of Sichuan Colun Botai Biomedicine, has been accepted by the China National Drug Administration. This drug is an antibody-drug conjugate targeting human epidermal growth factor receptor 2 and is used to treat adult patients with HER2-positive unresectable or metastatic breast cancer who have received anti-HER2 treatment. Based on a multicenter, randomized, open, and controlled phase III clinical study, bodutrastuzumab showed significant improvements in statistics and clinical significance in survival without progression at the end of the main study.

Colon Pharmaceutical announced that the application for a new drug of the company's holding subsidiary, Bodutrastuzumab, the core product of Sichuan Colun Botai Biomedicine, has been accepted by the China National Drug Administration. This drug is an antibody-drug conjugate targeting human epidermal growth factor receptor 2 and is used to treat adult patients with HER2-positive unresectable or metastatic breast cancer who have received anti-HER2 treatment. Based on a multicenter, randomized, open, and controlled phase III clinical study, bodutrastuzumab showed significant improvements in statistics and clinical significance in survival without progression at the end of the main study.